Literature DB >> 20956828

Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California/Van Nuys Prognostic Index.

Melvin J Silverstein1, Michael D Lagios.   

Abstract

The University of Southern California/Van Nuys Prognostic Index is an algorithm that quantifies five measurable prognostic factors known to be important in predicting local recurrence in conservatively treated patients with ductal carcinoma in situ (tumor size, margin width, nuclear grade, age, and comedonecrosis). With three times as many patients since originally developed, sufficient numbers now exist for analysis by individual scores rather than groups of scores. To achieve a local recurrence rate of less than 20% at 12 years, these data support excision alone for all patients scoring 4, 5, or 6 and patients who score 7 but have margin widths ≥ 3 mm. Excision plus RT achieves the less than 20% local recurrence requirement at 12 years for patients who score 7 and have margins < 3 mm, patients who score 8 and have margins ≥ 3 mm, and for patients who score 9 and have margins ≥ 5 mm. Mastectomy is required for patients who score 8 and have margins < 3 mm, who score 9 and have margins < 5 mm, and for all patients who score 10, 11, or 12 to keep the local recurrence rate less than 20% at 12 years. These recommendations in this article represent substantial changes from those previously published.

Entities:  

Mesh:

Year:  2010        PMID: 20956828      PMCID: PMC5161065          DOI: 10.1093/jncimonographs/lgq040

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  4 in total

1.  Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast.

Authors:  Susan C Lester; Shikha Bose; Yunn-Yi Chen; James L Connolly; Monica E de Baca; Patrick L Fitzgibbons; Daniel F Hayes; Celina Kleer; Frances P O'Malley; David L Page; Barbara L Smith; Donald L Weaver; Eric Winer
Journal:  Arch Pathol Lab Med       Date:  2009-01       Impact factor: 5.534

2.  Prognostic classification of breast ductal carcinoma-in-situ.

Authors:  M J Silverstein; D N Poller; J R Waisman; W J Colburn; A Barth; E D Gierson; B Lewinsky; P Gamagami; D J Slamon
Journal:  Lancet       Date:  1995-05-06       Impact factor: 79.321

3.  The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast.

Authors:  Melvin J Silverstein
Journal:  Am J Surg       Date:  2003-10       Impact factor: 2.565

4.  A prognostic index for ductal carcinoma in situ of the breast.

Authors:  M J Silverstein; M D Lagios; P H Craig; J R Waisman; B S Lewinsky; W J Colburn; D N Poller
Journal:  Cancer       Date:  1996-06-01       Impact factor: 6.860

  4 in total
  25 in total

Review 1.  Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions.

Authors:  Lawrence J Solin
Journal:  Curr Oncol Rep       Date:  2019-03-05       Impact factor: 5.075

2.  Biology, treatment, and outcome in very young and older women with DCIS.

Authors:  Rosalinda Alvarado; Sara A Lari; Robert E Roses; Benjamin D Smith; Wei Yang; Elizabeth A Mittendorf; Banu K Arun; Anthony Lucci; Gildy V Babiera; Jamie L Wagner; Abigail S Caudle; Funda Meric-Bernstam; Rosa F Hwang; Isabelle Bedrosian; Kelly K Hunt; Henry M Kuerer
Journal:  Ann Surg Oncol       Date:  2012-05-24       Impact factor: 5.344

3.  Benefit of tamoxifen in estrogen receptor positive DCIS of the breast.

Authors:  Petrelli Fausto; Sandro Barni
Journal:  Gland Surg       Date:  2012-05

4.  Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions.

Authors:  Chieh-Yu Lin; Kelly Mooney; Winward Choy; Soo-Ryum Yang; Keegan Barry-Holson; Kathleen Horst; Irene Wapnir; Kimberly Allison
Journal:  Mod Pathol       Date:  2017-12-15       Impact factor: 7.842

5.  Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.

Authors:  Lawrence J Solin; Robert Gray; Lorie L Hughes; William C Wood; Mary Ann Lowen; Sunil S Badve; Frederick L Baehner; James N Ingle; Edith A Perez; Abram Recht; Joseph A Sparano; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

6.  Factors contributing to underuse of radiation among younger women with breast cancer.

Authors:  I-Wen Pan; Benjamin D Smith; Ya-Chen Tina Shih
Journal:  J Natl Cancer Inst       Date:  2013-12-07       Impact factor: 13.506

7.  Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches.

Authors:  Nicolien T van Ravesteyn; Jeroen J van den Broek; Xiaoxue Li; Harald Weedon-Fekjær; Clyde B Schechter; Oguzhan Alagoz; Xuelin Huang; Donald L Weaver; Elizabeth S Burnside; Rinaa S Punglia; Harry J de Koning; Sandra J Lee
Journal:  Med Decis Making       Date:  2018-04       Impact factor: 2.583

8.  Variation in detection of ductal carcinoma in situ during screening mammography: a survey within the International Cancer Screening Network.

Authors:  Elsebeth Lynge; Antonio Ponti; Ted James; Ondřej Májek; My von Euler-Chelpin; Ahti Anttila; Patricia Fitzpatrick; Alfonso Frigerio; Masaaki Kawai; Astrid Scharpantgen; Mireille Broeders; Solveig Hofvind; Carmen Vidal; Maria Ederra; Dolores Salas; Jean-Luc Bulliard; Mariano Tomatis; Karla Kerlikowske; Stephen Taplin
Journal:  Eur J Cancer       Date:  2013-09-13       Impact factor: 9.162

Review 9.  Ductal Carcinoma In Situ of the Breast: Evaluating the Role of Radiation Therapy in the Management and Attempts to Identify Low-risk Patients.

Authors:  Chirag Shah; Frank A Vicini; Sameer Berry; Thomas B Julian; John Ben Wilkinson; Simona F Shaitelman; Atif Khan; Steven E Finkelstein; Neal Goldstein
Journal:  Am J Clin Oncol       Date:  2015-10       Impact factor: 2.339

10.  DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breast.

Authors:  R Souchon; M-L Sautter-Bihl; F Sedlmayer; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; W Harms; F Wenz; R Sauer
Journal:  Strahlenther Onkol       Date:  2014-01       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.